On 11 January, the company TauRx Therapeutics Ltd announced it has completed the patient enrolment of its Lucidity Phase III trial for the treatment of Alzheimer’s disease (AD). The Lucidity trial is a randomised, double-blind and placebo-controlled study evaluating the safety and efficacy of hydromethylthionine in people with AD encompassing mild cognitive impairment due to AD in US, Canada and Europe. Hydromethylthionine acts by blocking abnormal accumulation of Tau protein in the brain. Lucidity is the only late-stage study targeting the tau pathology of AD.
More than 500 research participants have been enrolled. They are receiving oral capsules (8 or 16mg/day of hydromethylthionine or placebo) twice daily for 52 weeks. The primary outcomes of the study are progression of cognitive decline and functional impairment over 12 months measured by standard clinical scales. Results are expected to be available by mid-2022.